玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿的临床疗效分析

目的 探究玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿(DME)的临床疗效.方法 70例顽固性DME患者,随机分为对照组及观察组,每组35例.对照组玻璃体内注射雷珠单抗,观察组玻璃体内注射阿柏西普.对比两组黄斑中心凹视网膜厚度(CFT)、最佳矫正视力(BCVA)、眼压及不良反应发生情况.结果 术后1、2个月,两组CFT...

Analysis of the clinical efficacy of intravitreal injection of aflibercept on refractory diabetic macular edema

Objective To study the clinical efficacy of intravitreal injection of aflibercept on refractory diabetic macular edema(DME).Methods A total of 70 patients with refractory DME were randomly divided into control group and observation group,with 35 cases in each group.The control group was injected intravitreously with ranibizumab,and the observation group was injected intravitreously with aflibercept.The central foveal thickness(CFT),best corrected visual acuity(BCVA),intraocular pressure and occurrence of adverse reactions were compared between the two groups.Results At 1 and 2 months after operation,the CFT of the two groups was smaller than that of this group before operation;the CFT of the observation group were(224.83±21.75)and(192.27±18.64)μm,which was smaller than(290.42±22.34)and(276.43±20.55)μm of the control group;all the differences were statistically significant(P<0.05).At 1 and 2 months after operation,the BCVA of the two groups was higher than that of this group before operation;the BCVA of the observation group were(0.51±0.12)and(0.55±0.11)log MAR,which was higher than(0.35±0.10)and(0.38±0.12)log MAR of the control group;all the differences were statistically significant(P<0.05).At 1 and 2 months after operation,the intraocular pressures of the observation group were(15.39±1.58)and(15.03±1.47)mm Hg(1 mm Hg=0.133 kPa),which were lower than(16.24±1.23)and(16.07±1.34)mm Hg of the control group,and the difference was statistically significant(P<0.05).Conclusion Intravitreal injection of aflibercept is beneficial to improve the BCVA,CFT and intraocular pressure level of patients with refractory DME.No complications occurred during the treatment.The short-term efficacy is good and the drug effect is stable.